Tamoxifen benefits women who have had invasive breast cancer, community study finds
BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5442 (Published 07 October 2016) Cite this as: BMJ 2016;355:i5442- Jacqui Wise
- London
Women with invasive breast cancer should be encouraged to complete the full course of oestrogen blocking drugs to lower the risk of developing cancer in the other breast, researchers have said.
Their retrospective cohort study, published in JAMA Oncology, showed that treating women with invasive breast cancer with tamoxifen or aromatase inhibitors could lower the risk of contralateral breast cancer, especially among women whose breast cancer was oestrogen receptor positive.1
The study, which was the first to be carried out in a general community …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.